Amber Bio
About Amber Bio
Amber Bio develops novel gene editing modalities capable of performing multi-kilobase edits to address previously undruggable patient populations. The company is creating a first-of-its-kind RNA writing platform designed to treat thousands of diverse mutations with a single therapeutic product. This approach moves beyond developing separate therapies for individual mutations in genetic medicine.
```xml <problem> Current genetic medicine approaches often require developing separate therapies for each mutation within a patient population. This approach is not scalable and leaves many patients with previously undruggable conditions. </problem> <solution> Amber Bio is developing an RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. Their approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine. The company's platform is designed to be safe and reversible, allowing for larger edits than current gene editing technologies. By studying biological systems and applying biological design principles, Amber Bio aims to create gene therapies that are safe, easy, precise, and affordable. </solution> <features> - RNA writing platform capable of editing thousands of diverse mutations across patients with a single product - Multi-kilobase edits for addressing previously undruggable conditions - Designed for safe and reversible gene editing - Biologically inspired approach leveraging sophisticated biological systems - Focus on creating gene therapies that are safe, easy, precise, and affordable </features> <target_audience> Amber Bio's primary target audience includes patients with genetic diseases and the biotechnology companies developing genetic medicines. </target_audience> ```
What does Amber Bio do?
Amber Bio develops novel gene editing modalities capable of performing multi-kilobase edits to address previously undruggable patient populations. The company is creating a first-of-its-kind RNA writing platform designed to treat thousands of diverse mutations with a single therapeutic product. This approach moves beyond developing separate therapies for individual mutations in genetic medicine.
Where is Amber Bio located?
Amber Bio is based in San Francisco, United States.
When was Amber Bio founded?
Amber Bio was founded in 2021.
How much funding has Amber Bio raised?
Amber Bio has raised $26.0M.
- Location
- San Francisco, United States
- Founded
- 2021
- Funding
- $26.0M
- Employees
- 20 employees
- Investors
- Playground GlobalAndreessen HorowitzHummingbird VC
